Toy Andrew sold $293K of CLOV

Toy Andrew (Chief Executive Officer) sold 62,711 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 ($0.29M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Toy Andrew
Published Jul 16, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 designation generally reduces the likelihood of a fundamental repricing.

02

Market read

A new, primary-source insider sale is disclosed, but it is pre-arranged under 10b5-1, so expected impact is limited.

03

What to watch

The filing does not disclose reasons for the sale, and the post-transaction share count remains large, limiting inference from a single sale.

Relevance 3/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-16) discloses the 2026-07-15 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp. /DE.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Toy Andrew sold 62,711 shares on 2026-07-15 at $4.6700, per a new SEC Form 4 filing.

Expected impact

Likely minimal price impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.

Key entities

  • Clover Health Investments, Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • Toy Andrew

    CEO and officer/director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that typically limits interpretive value of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.